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Abstract
Human hepatocellular carcinoma is one of the most frequent malignant tumors. It may occur following exposure to
various agents, including viruses and chemical carcinogens; however, the underlying mechanisms of the hepatocarcinogenesis
are not known. The present study is the result of our search for genes which may be abundantly expressed in human primary
liver carcinoma. One of these genes was found to encode the human hepatocyte growth factor-like protein (HGFLP), also
known as macrophage-stimulating protein. HGFLP is structurally homologous to hepatocyte growth factor, a potent growth
factor for liver. HGFLP mRNA was also found to be overexpressed in a hepatoblastoma sample and in a sample of subacute
fulminant hepatic necrosis. In a study on the effects of cytokines on the expression of HGFLP, we found that IL-6 increased
expression of HGFLP mRNA in Hep G2 cells, but IL-1K, IL-1L and TNF-K had no effect. An increase in HGFLP could be
the result of inflammation and/or tissue injury and its overexpression may prove to be useful as an indicator of
hepatoma. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Hepatocellular carcinoma (HCC) is a widespread
disease, its annual incidence being estimated between
0.25 and 1 million new cases per year [1]. Etiological
studies have shown that the occurrence of HCC is
related to factors such as hepatitis B virus or hepa-
titis C virus infection, a£atoxin B1, and hepatic cir-
rhosis [2^6]. These factors can cause mutations in the
structural and regulatory genes of hepatocytes, and
result in the abnormal expression of cellular genes. It
is believed that hepatocyte necrosis and the prolifer-
ation process (liver regeneration) resulting from
chronic liver disease are also involved in the develop-
ment of HCC. While growth factors such as epider-
mal growth factor, transforming growth factor-K,
hepatocyte growth factor (HGF) and transforming
growth factor-L, and protooncogene products, such
as c-fos, c-myc, p53, and the ras gene family (c-Ha-
ras, c-Ki-ras, and N-ras) are regulators during liver
regeneration [7^10], aberrant expression of these
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genes is of clinical signi¢cance in the development of
HCC [11^14]. Cytokines, such as interleukin-6 (IL-
6), which are involved in the acute phase response
and liver regeneration [15,16], may also be involved.
It is likely that a complex interplay of regenerative
cell growth induced by hepatic in£ammatory disease,
consequences of viral integration and chromosomal
alterations, as well as genetic and environmental host
factors, all participate in the development of the ma-
lignant phenotype.
The identi¢cation of markers for HCC with in-
creased expression in advanced lesions would be ex-
tremely useful in the detection of tumors or in the
evaluation of prognosis. However, there is still lim-
ited information available on genes associated with
HCC. In the present work we used cDNA subtrac-
tion hybridization [17] to identify genes which are
overexpressed in liver tumor tissue when compared
to the corresponding normal tissue. As altered gene
expression is a common feature of neoplastic cells,
we found by this method genes which are more
abundantly expressed in liver tumor cells when com-
pared to normal cells. In this article, we report an
increase in expression of hepatocyte growth factor-
like protein (HGFLP), a protein with structural sim-
ilarities to HGF [18], in liver tumor cells. We also
report the e¡ect of treatment by several cytokines on
the expression of HGFLP mRNA in Hep G2 cells.
2. Materials and methods
2.1. Liver samples
The liver sample used as a source of mRNA for
the tumor cDNA library was a primary hepatocellu-
lar carcinoma from a patient who was also positive
for hepatitis B virus. Other liver samples used to
examine the expression level of the isolated clones
were obtained from a hepatocellular carcinoma pa-
tient with hepatitis and the non-tumorous liver tissue
from the same patient, from a rectum carcinoma
patient with tumor metastasized to the liver and
the uninvolved liver part from the same patient,
from a hepatoblastoma patient, from a malignant
hemangioendothelioma patient, the uninvolved liver
parts from two colon carcinoma patients with tumor
metastasized to the liver. These samples were ob-
tained through the Cooperative Human Tissue Net-
work, University of Alabama at Birmingham. Two
liver specimens with fulminant hepatic failure, one
with chronic active hepatitis, and one with subacute
fulminant hepatic necrosis were obtained from Dr.
R.M. Galbraith, Medical University of South Caro-
lina. Samples were obtained with the approval of,
and in accordance with, guidelines established by
the Medical University of South Carolina Institu-
tional Review Board for Human Research.
2.2. Cell lines
Hepatoma cell lines Hep G2 and Hep 3B were
obtained from American Type Culture Collection
(Rockville, MD), and were cultured in Eagle’s mini-
mal essential medium (MEM) (Hazleton, Lenexa,
KS) supplemented with 10% fetal calf serum (FCS)
(Hyclone, Logan, UT) in 75-cm2 £asks at 37‡C in
humidi¢ed atmosphere containing 5% CO2 in air.
The cells were allowed to grow to about 80% con-
£uence before extraction of the total RNA. THP1
monocytes (from Dr. J.M. Goust, Medical Univer-
sity of South Carolina) were cultured in RPMI 1640
medium supplemented with 10% fetal calf serum.
Cultured human foreskin ¢broblasts were kindly pro-
vided by Dr. Maria Trojanowska, Medical Univer-
sity of South Carolina.
2.3. RNA preparation and tumor cDNA library
construction
Total cellular RNA was isolated from tissues by
the guanidinium thiocyanate procedure [19,20].
RNAs from cell lines were extracted with a modi¢ed
version of this procedure using an RNAsol B kit
(Biotecx, Houston, TX) or an Ultraspect RNA kit
(Biotecx) according to the manufacturer’s protocol.
Polyadenylated RNA was puri¢ed through two
cycles of binding to and elution from an oligo-dT
cellulose column [21]. First and second strand
cDNA synthesis from liver tumor mRNA were per-
formed essentially according to the procedure of Gu-
bler and Ho¡man [22], using a kit from Gibco BRL
(Gaithersburg, MD). The cDNA was blunt-ended by
Klenow fragment, and size-selected on a Sephacryl
S-400 spin column (Pharmacia, Piscataway, NJ). An
EcoRI/NotI adapter was ligated to each end of the
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cDNA by T4 DNA ligase (Stratagene, La Jolla, CA).
The DNA was then ligated to pre-prepared V ZAP II
arms, and the V ZAP II phage DNA was packaged
with Gigapack II packaging extracts (Stratagene) ac-
cording to the supplier’s protocol.
2.4. Subcloning procedure for non-tumor cDNA
A non-tumoral human liver cDNA library in V gt
11 was purchased from Clontech (Palo Alto, CA).
We subcloned the cDNA inserts from this library
into V ZAP II vector. The cDNA inserts were
PCR-ampli¢ed using forward and reverse primers
(New England Biolabs, Beverly, MA) with sequences
complementary to sites adjacent to the EcoRI site in
the V gt 11 vector. EcoRI digestion was then per-
formed to generate EcoRI sites at both ends of the
inserts for the cloning, and the inserts were then
puri¢ed on a Sephadex G-50 column. The cDNA
inserts were then ligated into EcoRI-digested V
ZAP II arms as described above, followed by pack-
aging and infection of XL1-Blue cells.
2.5. Subtractive hybridization
cDNA library subtraction was performed by the
protocol of Schweinfest et al. [17]. Biotinylation
was according to Duguid et al. [23] and two rounds
of streptavidin subtraction were performed according
to Sive and St. John [24].
2.6. DNA dot blot analysis
Poly(A) RNAs prepared from both tumor liver
and non-tumor liver tissues were used as templates
for the synthesis of 32P-labeled ¢rst strand cDNA
[25]. Plasmid DNA from each clone in the subtrac-
tive library was prepared by a mini-prep procedure
[26]. Five Wg of each DNA were applied onto a Ny-
tran membrane (Schleicher and Schuell, Keene, NH)
and cross-linked in a Stratalinker (1200 J/cm2) (Stra-
tagene). Duplicate dot blot membranes were allowed
to hybridize with the radiolabeled cDNA probes
from tumorous and non-tumorous liver.
2.7. DNA partial sequencing and computer analysis
The cDNA inserts were sequenced using a cycle
sequencing protocol (Gibco BRL). Primers were de-
signed according to sequences in pBluescript vector
£anking the EcoRI site (Primer SK, CTCTAGAAC-
TAGTGGATCCC; Primer KS, GGTATCGATAA-
GCTTGATATC), and were labeled at the 5P-ends
with T4 kinase according to the manufacturer’s pro-
tocol (Gibco BRL). Sequences obtained were exam-
ined for similarity in the GenBank nucleic acid data-
base through the ‘Basic Local Alignment Search
Tool’ (BLASTN) program for nucleotide compari-
son.
2.8. Cell culture and cytokine treatment
Hep G2 cells were cultured in MEM supplemented
with penicillin (50 U/ml), streptomycin (50 Wg/ml)
and 10% FCS. The cells were plated on 6-well plastic
plates and incubated at 37‡C in a humidi¢ed atmos-
phere of 5% CO2 in air. To study the e¡ect of cyto-
kines on the expression of clone 18 (HGFLP), 1U106
cells per well were incubated in MEM medium with
10% FCS and were allowed to grow until 95% con-
£uent. The cells were then preincubated with serum-
free MEM for 4 h to remove residual serum [27].
Following preincubation, the cells were incubated
with serum-free MEM alone or MEM containing
the cytokine to be tested. The cytokines tested were
recombinant human IL-1K and IL-1L (RpD, Minne-
apolis, MN), TNF-K (Gibco BRL, Gaithersburg,
MD), and IL-6 (Genzyme, Cambridge, MA).
2.9. Northern blot hybridization
The cDNA inserts of selected subtractive clones
were released from the pBluescript vector by either
NotI or EcoRI digestion. The cDNA inserts were
eluted from the agarose gel by centrifugation
through silanized glass wool at 2500 rpm for 20 min
[21], and were labeled by the random primer labeling
procedure with 32P [28], using the Prime-It II kit
(Stratagene). The probes were then puri¢ed by etha-
nol precipitation. Ten or 20 Wg of total RNA from
each sample were fractionated by electrophoresis on
1.2% agarose gels containing 6% formaldehyde [21].
After completion of electrophoresis, the gels were
stained with ethidium bromide, illuminated with
UV light and photographed to verify equal loading
of rRNA bands. The denatured RNA was then
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transferred to Nytran membranes by capillary elu-
tion [21]. After overnight transfer, the membranes
were photographed under UV light in order to verify
equal transfer of ethidium bromide-stained riboso-
mal RNA bands. The RNA was then cross-linked
to the membrane as described above. Hybridization
and washing were performed as described [29]. The
¢lter was autoradiographed using tungstate intensi-
¢er screens at 370‡C for various periods of time.
3. Results
3.1. Preliminary screening of the subtraction
library-di¡erential DNA hybridization
A total of 87 tumor enriched subtracted recombi-
nant cDNAs were obtained. Among these 87 clones,
only some of them were expected to be speci¢c for
liver tumor. As a ¢rst step in analyzing our clones,
DNA di¡erential hybridization was used to identify
tumor-speci¢c sequences on dot blots. We used the
¢rst strand cDNAs synthesized from the non-tumor
and tumor liver RNAs as probes to hybridize to each
clone, respectively. A number of the clones displayed
increased hybridization signal intensity with the tu-
mor cDNA probe in this preliminary screening, but
none were found to hybridize only to the tumor
probe (not shown). Partial sequence analysis was
performed on selected recombinants from the sub-
tractive library, and the sequence of each was com-
pared to the Genbank nucleic acid database through
the BLASTN program. Clone 18 was found to be
HGFLP.
3.2. Complete sequencing of clone 18
The complete sequence of clone 18 is 908 bp in
length, and has 97.6% identity with the published
sequence for the HGFLP gene. When compared
with the published cDNA sequences and the trans-
lated amino acid sequences of the cDNA coding for
human HGFLP [18], the clone 18 insert is located at
the 3P-end of the HGFLP cDNA which encodes for
the serine protease-like domain. This particular tran-
script still contained introns M and N, but not O, P
or Q. In addition, this clone contained 47 nucleotides
from the DNF15S1 locus [30], suggesting that this
transcript came from chromosome 1 and not from
chromosome 3. These chromosome 1-speci¢c se-
quences begin 41 nucleotides 3P to the termination
codon and represent the boundary of an ancient
transposition and duplication of the HGFLP gene
from chomosome 3 [30].
3.3. Northern blot analysis of tumors and cell lines
The clone 18 cDNA insert was released by Not I
digestion, puri¢ed by agarose gel electrophoresis, la-
beled with K-32P dATP and used as a probe to hy-
bridize to the total RNAs from tumor and non-tu-
mor liver tissues (Fig. 1). Clone 18, (HGFLP) clearly
hybridized to a 2.4 kb mRNA species from tumor
liver more strongly than for non-tumor liver. Clone
18 also hybridized to mRNA from Hep 3B cells and
Hep G2 cells, but no bands were seen for foreskin
¢broblast RNA (Fig. 2A, lanes 1^3). An additional
band of 3.0 kb mRNA was also seen for the Hep 3B
and Hep G2 cells as well as for some of the other
samples (see below). The tumor RNA yielded a
stronger signal than the non-tumor RNA, thus sug-
gesting that HGFLP was expressed at an increased
level in HCC. In addition, our results showed that,
unlike HGF [31], the protein to which HGFLP is
similar in structure, HGFLP is expressed by both
Hep G2 and Hep 3B hepatoma cell lines.
Fig. 1. Northern blot analysis of clone 18 expression. Twenty
Wg of total RNA of liver tumor (lane 1) and non-tumor liver
(lane 2) were loaded on each well and transferred to a Nytran
¢lter after electrophoresis. The Northern blot was probed with
clone 18 insert. RNA sizes shown on the left margin, were esti-
mated by comparison with a 0.24^9.5 kb RNA ladder. The po-
sitions of the rRNAs are shown on the right margin.
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We then examined the expression of HGFLP
mRNA in other liver tumor and non-invaded parts
from the same liver, as well as in tissues from other
liver diseases by means of Northern blot hybridiza-
tion (Fig. 2B). We found that the level of HGFLP
expression was higher in another HCC sample (lane
1) than in the corresponding normal liver tissue from
the same patient (lane 2). The expression level of
HGFLP was found to be even higher in a hepato-
blastoma sample (lane 6). In addition, the 3.0-kb
mRNA species could be detected in this tumor sam-
ple. By contrast, HGFLP expression levels in non-
hepatocyte derived tumors (liver metastasis of a rec-
tal carcinoma, lane 3; hemangioendothelioma (a vas-
cular tumor) from liver, lane 5) appeared to be lower
than that for uninvolved liver tissues (lanes 2 and 4).
This is in agreement with HGFLP in the liver being
produced only by hepatocytes [32]. The faint bands
seen in lanes 3 and 5 are likely to originate from the
normal hepatocytes surrounding the metastasis. No
mRNA expression was observed either in two non-
tumorous liver samples from patients with colon car-
cinoma (lanes 7 and 8) or in the THP1 monocytes
(lane 13).
We also examined HGFLP mRNA expression in
liver samples from chronic hepatic diseases and ful-
minant hepatic failure (lanes 9^12). We found that
no HGFLP could be detected in the fulminant hep-
atic failure samples (lanes 10 and 11). The metabo-
lism of these hepatocytes may be drastically altered
as a result of cell necrosis. As shown on lanes 9 and
12, corresponding to chronic active hepatitis and
subacute hepatic necrosis samples, respectively,
some HGFLP was produced by these livers.
3.4. E¡ect of IL-6 on HGFLP mRNA expression in
Hep G2 cells
To determine the e¡ect of IL-6 on the expression
of the HGFLP mRNA by Hep G2 cells, 70% con-
£uent Hep G2 cells were incubated with serum-free
MEM medium alone, or with IL-6 at a concentration
of 25 ng/ml. Total cellular RNAs were extracted at
di¡erent time points of 12, 24, 36, 48, and 60 h. Ten
Wg of total RNA were loaded and fractionated by
agarose/formaldehyde gel electrophoresis. Equal
loading of the gel was determined from ethidium
Fig. 3. Northern blot of time course of the IL-6 e¡ect on the
expression of HGFLP mRNA. (A) Northern blot probed with
HGFLP. Hep G2 cells were treated with 25 ng/ml of IL-6 for
12 h (lane 2), 24 h (lane 3), 36 h (lane 4), 48 h (lane 5) and 60
h (lane 6), and 10 Wg of total RNA was loaded on each well.
Lane 1 is the untreated Hep G2 RNA. (B) The Northern blot
¢lter was probed with human L-actin.
Fig. 2. Northern blot analysis of clone 18 (HGFLP) in other HCC samples, as well as di¡erent liver diseases and cell lines. (A) Lane
1, RNA from Hep 3B cells ; lane 2, RNA from Hep G2 cells ; lane 3, RNA from foreskin ¢broblast cells. (B) Lane 1, RNA from a
hepatocellular carcinoma with hepatitis ; lane 2, RNA from non-tumor liver tissue from the same patient; lane 3, RNA from rectum
carcinoma metastasized to liver; lane 4, RNA from uninvolved liver from the same patient; lane 5, RNA from liver hemangioendo-
thelioma; lane 6, RNA from hepatoblastoma; lanes 7 and 8, RNA from two non-tumorous liver samples from patients with colon
carcinoma; lane 9, RNA from chronic active hepatitis liver sample; lanes 10 and 11, RNA from two liver samples from patients with
fulminant hepatic failure; lane 12, RNA from a liver sample of subacute fulminant hepatic necrosis ; lane 13, RNA from the mono-
cyte cell line THP1. The positions of RNA markers are shown as for Fig. 1.
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bromide staining of the gel and the Nytran mem-
brane after the Northern transfer. As shown in Fig.
3, HGFLP mRNA expression was increased time
dependently as compared to the L-actin control after
IL-6 treatment in Hep G2 cells. The increase in
HGFLP expression was already detectable after
12 h treatment of IL-6, and reached the highest level
at 24 h. The expression level was still higher at 60 h
than for the untreated samples. The maximum extent
of the increase in mRNA expression at 24 h after the
treatment was estimated to be about two to three
fold. The increase in HGFLP mRNA expression by
IL-6 was also dose-dependent as compared to the
L-actin control. As Fig. 4 shows, we treated the
Hep G2 cell with IL-6 at the concentration of 2.5,
5.0, 10.0, 25.0, 50.0 and 100.0 ng/ml, respectively,
and extracted the RNA after a 48-h incubation.
HGFLP mRNA was elevated with 2.5 ng/ml IL-6,
reached the maximum at an IL-6 concentration of
25 ng/ml, and stayed at the same level even in the
presence of 100 ng/ml of IL-6. The above indicates
that IL-6 stimulates the transcription of HGFLP in a
time- and dose-dependent manner. Similar time (up
to 48 h) and dose-dependent (2.5^100 ng) experi-
ments were performed for IL-1K, IL-1L and TNF-
K. In contrast to the results for IL-6, IL-1K, IL-1L
And TNF-K had no signi¢cant e¡ect on the expres-
sion of HGFLP mRNA in Hep G2 cells (data not
shown).
In summary, the above results suggest that
HGFLP mRNA can only be detected in hepatocytes
in our experiments and not in other cell types, such
as monocytes, or rectal cancer cells. The mRNA of
HGFLP is decreased in the fulminant hepatic failure
sample, as also reported by others [33], and appears
to be increased in the subacute hepatic necrosis sam-
ple. The above results also suggest that HGFLP is
overexpressed in human hepatocellular carcinoma as
well as in hepatoblastoma. Finally, IL-6, but not the
other cytokines tested, increases the expression of
HGFLP mRNA in Hep G2 cells.
4. Discussion
Subtraction hybridization as a means for cloning a
speci¢c subset of mRNA sequences has been applied
successfully to a wide range of biological problems
and has proven to be very e⁄cient in isolating se-
quences expressed di¡erentially between two di¡erent
tissues [17,23,34^38]. Using subtraction hybridiza-
tion, we identi¢ed sequences that are expressed at
increased levels in HCC, one of which was HGFLP.
HGFLP was ¢rst described by Han et al. [18] and
was named hepatocyte growth factor-like protein be-
cause its structural organization is similar to HGF, a
growth factor with broad target speci¢city [39]. The
two proteins each contain four kringle domains fol-
lowed by a serine protease-like domain and have
50% homology in amino acid sequence. More re-
cently, HGFLP was reported to be identical to a
macrophage-stimulating protein (MSP) [40,41].
MSP is the name originally given to a human serum
protein that makes resident peritoneal mouse macro-
phages capable of responding to the chemoattractant
C5a [42].
A striking feature of the sequence of clone 18 is
that this cDNA clone still retains some introns and
contains sequences from the DNF15S1 locus in chro-
mosome 1. This is a situation that was also observed
by Yoshimura et al. [41] for some of their MSP
cDNA clones. The human HGFLP/MSP genes ex-
press two mRNAs species of 2.4 and 3.0 kb [18],
and the clone 18 probe revealed the same expression
pattern, again indicating the likelihood for retained
introns or other alternatively spliced species [41]. The
junction sequence we see in the 3P-untranslated re-
gion of our clone is thought to be due to an ancient
transposition of chromosome 3 sequences containing
the HGFLP/MSP gene to chromosome 1 [30] with
the sequences upstream of the junction remaining
virtually identical [41] in the duplicated genes. Per-
Fig. 4. Northern blot of dose response of IL-6 e¡ect on the ex-
pression of HGFLP mRNA. (A) Hep G2 cells were incubated
with IL-6 at the concentration of 2.5 ng/ml (lane 2), 5.0 ng/ml
(lane 3), 10.0 ng/ml (lane 4), 25.0 ng/ml (lane 5), 50.0 ng/ml
(lane 6) and 100.0 ng/ml (lane 7) for 48 h. Lane 1 shows the
untreated Hep G2 RNA. Ten Wg of total RNA was used in the
Northern hybridization. (B) The Northern blot ¢lter was
probed with human L-actin.
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haps the di¡ering 3P-sequences for the chromosome
1 genes cause the pre-mRNA to be less e⁄ciently
processed, resulting in a buildup of mRNA species
that still retain some of their introns. The relative
contributions to functional HGFLP from these genes
is not known. It remains to be determined whether
mRNA from chomosome 1 is more often mispro-
cessed and perhaps represents the bulk of the 3.0
kb RNA.
The mRNA for the HGF has been identi¢ed in
rats in several tissues, including brain, lung, heart,
thymus, liver, spleen, and kidney tissue [43]. In the
liver, HGF mRNA is present in non-parenchymal
fat-storing cells [44], and its expression increases fol-
lowing partial hepatectomy in rats [45,46]. In con-
trast to the widespread expression pattern of HGF,
HGFLP was reported to be expressed primarily in
the liver in embryonic and adult mice and rats
[18,47], where it is synthesized by hepatocytes [32].
In our experiments, expression of HGFLP was found
in liver (both normal and tumor) and in hepatoma
cell lines (Hep G2 and Hep 3B), but not in foreskin
¢broblast or monocytes. This is in agreement with
the results of others that HGFLP expression is pri-
marily in the liver [47].
The similarity in protein structure between
HGFLP and HGF suggests that they might function
in cell growth regulation in a similar manner. How-
ever, their ultimate biological role is likely to be dif-
ferent since they are produced by di¡erent cell types.
A possible function of HGFLP/MSP might be its
involvement in protective responses during the in-
£ammatory reactions caused by infections, tissue in-
jury [40], and malignancy through activation of mac-
rophages. Bezzera et al. [48] have found that HGFLP
mRNA is increased during liver regeneration and
in£ammation as well as in turpentine-induced acute
phase response in rats. In this regard, we have found
that IL-6, a major acute phase response regulatory
cytokine, causes an increase in HGFLP mRNA in
Hep G2 cells. However, Wang et al. [49] have shown
that serum MSP is not increased in lipopolysaccha-
ride-challenged human subjects, leaving the acute
phase reactant nature of HGFLP/MSP open for fur-
ther study. These authors [49,50] suggest a model in
which the protein circulates as pro-MSP and, upon
conversion to MSP [51], would cause transient acti-
vation of tissue macrophages, presumably by binding
to the RON tyrosine kinase receptor [52^55]. In fact,
putative IL-6 response elements [56] were found in
the RON gene promoter [57] and can also be seen at
positions (3525) and (3715) in the HGFLP pro-
moter [58] ; the latter giving validity to our ¢nding
of IL-6 induction of HGFLP mRNA.
In our results for treatment of Hep G2 cells, while
HGFLP mRNA expression was increased by IL-6,
IL-1K, IL-1L and TNF-K had no e¡ect. This is the
exact opposite of what Tamura et al. [59] found for
HGF expression in human ¢broblasts where IL-1K,
IL-1L, and TNF-K all increased expression whereas
IL-6 had no e¡ect. IL-6, IL-1K, IL-1L and TNF-K
are all involved in the acute phase response reaction
and liver repair and regeneration process, and IL-6 is
the major mediator of these responses. Thus the two
proteins, HGFLP and HGF, may both act as growth
factors, but act on di¡erent cellular targets and are
regulated di¡erently as well.
HGFLP/MSP activates macrophages and thus can
play a role in the body’s self-defense. In turn, macro-
phages can produce and secrete cytokines, including
IL-6, and can trigger the function of the defense
system. Here we can see a positive feedback loop,
in which hepatocytes produce and secrete HGFLP/
MSP, and these proteins activate the macrophage
(and thus, speculatively, Kup¡er cells in liver) to
produce cytokines such as IL-1 and IL-6. IL-6 will
then further stimulate the production of HGFLP/
MSP. That MSP can speci¢cally induce IL-6 in cells
bearing the RON receptor has been shown for exam-
ple in megakaryocytes [60].
In experimental models, IL-6 has been found to
stimulate the growth of human colorectal carcinoma
cell lines [61] and renal cell cancer [62], but inhibit
the growth of human breast cancer cell lines [63] and
human lung cancer cell lines [64]. Therefore, the role
of IL-6 in tumor biology appears to be di¡erent for
di¡erent kinds of tumors and is unknown for hepa-
tocellular carcinoma. In our experiments, HGFLP
was overexpressed in hepatocellular carcinoma. The
basis for the increased expression of HGFLP is not
readily apparent. Could this be the result of an in-
£ammatory reaction in which IL-6 expression was
increased, and in turn, IL-6 stimulated the expression
of HGFLP? Alternatively, HGFLP overexpression
could be the result of the malignancy, and the over-
expressed HGFLP is responsible for the continued
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development of the liver tumor via the macrophage
feedback loop. In either case, IL-6 might then be a
stimulator of liver cancer. Further study of the rela-
tionship between HGFLP and IL-6 and the roles
they play in liver malfunction may well reveal at least
part of the mechanism for hepatocarcinogenesis.
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